[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,563,601
  • Shares Outstanding, K 118,014
  • Annual Sales, $ 1,239 M
  • Annual Income, $ 210,000 K
  • EBIT $ 332 M
  • EBITDA $ 352 M
  • 60-Month Beta 0.86
  • Price/Sales 3.69
  • Price/Cash Flow 14.24
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 48.80% (+0.87%)
  • Historical Volatility 34.87%
  • IV Percentile 17%
  • IV Rank 35.14%
  • IV High 97.01% on 04/15/26
  • IV Low 22.67% on 09/05/25
  • Expected Move (DTE 14) 0.00 (0.00%)
  • Put/Call Vol Ratio 3.36
  • Today's Volume 109
  • Volume Avg (30-Day) 334
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 37,451
  • Open Int (30-Day) 36,644
  • Expected Range 38.82 to 38.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.93
  • Number of Estimates 1
  • High Estimate $0.93
  • Low Estimate $0.93
  • Prior Year $0.72
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.76 +8.56%
on 08/04/26
41.84 -7.23%
on 07/16/26
-2.01 (-4.92%)
since 07/07/26
3-Month
32.41 +19.78%
on 06/02/26
42.81 -9.32%
on 06/26/26
-0.78 (-1.97%)
since 05/07/26
52-Week
21.83 +77.83%
on 08/11/25
42.81 -9.32%
on 06/26/26
+16.77 (+76.05%)
since 08/07/25

Most Recent Stories

More News
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals...

INDV : 38.82 (+0.39%)
SUPN : 47.64 (+1.88%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

NEW YORK , Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

INDV : 38.82 (+0.39%)
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

INDV : 38.82 (+0.39%)
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenues Enhanced financial position and free cash flow...

INDV : 38.82 (+0.39%)
SUPN : 47.64 (+1.88%)
Indivior Reports Tomorrow With SUBLOCADE Deceleration Already Priced In But Margin Promise Still Unproven

Barchart Research What to Expect from INDV Earnings INDV Generated April 29, 2026 Current Price $34.15 EPS Estimate $$0.64 Consensus Rating Strong Buy Average Move 11.78% Indivior Reports Tomorrow With...

INDV : 38.82 (+0.39%)
S&P 500, MidCap 400, and SmallCap 600 Welcome New Members as Indexes Rebalance for 2026

The S&P 500’s latest rebalance reveals how the index quietly upgrades itself by promoting winners like Carvana and CRH and removing underperformers through a process that more closely resembles disciplined...

APP : 346.80 (+3.32%)
ENPH : 41.87 (+5.55%)
PRIM : 82.63 (+3.00%)
HL : 16.85 (+6.24%)
SOLS : 60.96 (-1.96%)
MKTX : 162.53 (-0.06%)
CHAR : 10.91 (+0.18%)
CWST : 89.41 (-1.16%)
UA : 5.93 (-5.42%)
BWA : 68.42 (+3.98%)
PRGO : 12.84 (+2.39%)
IRDM : 49.93 (+3.35%)
Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher

Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 Stocks to Buy. Up 192% in 2025, its P/E is declining despite the stock’s gains...

INDV : 38.82 (+0.39%)
Indivior Announces Inclusion in the S&P SmallCap 600® Index

RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) (" Indivior PLC " or the " Company ") today announced that it will be added to the S&P SmallCap 600 ® index,...

INDV : 38.82 (+0.39%)
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

RICHMOND, Va. , Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in  JAMA Network Open.  The...

INDV : 38.82 (+0.39%)
CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK , Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open...

PRIM : 82.63 (+3.00%)
HL : 16.85 (+6.24%)
SOLS : 60.96 (-1.96%)
CWST : 89.41 (-1.16%)
UA : 5.93 (-5.42%)
BWA : 68.42 (+3.98%)
PRGO : 12.84 (+2.39%)
IRDM : 49.93 (+3.35%)
MHK : 136.06 (+2.75%)
CEVA : 38.67 (+8.65%)
INDV : 38.82 (+0.39%)
DY : 407.99 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Indivior Pharmaceuticals Inc., together with its subsidiaries, develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders principally in the United States, Europe, Canada, Australia and internationally. Indivior Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 39.96
2nd Resistance Point 39.43
1st Resistance Point 39.13
Last Price 38.82
1st Support Level 38.30
2nd Support Level 37.77
3rd Support Level 37.47

See More

52-Week High 42.81
Last Price 38.82
Fibonacci 61.8% 34.80
Fibonacci 50% 32.32
Fibonacci 38.2% 29.84
52-Week Low 21.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.